Biohaven Ltd. $BHVN Shares Purchased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company raised its holdings in Biohaven Ltd. (NYSE:BHVN) by 52.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 202,975 shares of the company’s stock after purchasing an additional 69,894 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.13% of Biohaven worth $1,717,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in BHVN. Suvretta Capital Management LLC boosted its stake in shares of Biohaven by 83.0% during the fourth quarter. Suvretta Capital Management LLC now owns 10,286,937 shares of the company’s stock worth $116,140,000 after buying an additional 4,666,666 shares during the period. Stifel Financial Corp increased its position in Biohaven by 50.3% in the 4th quarter. Stifel Financial Corp now owns 9,939,856 shares of the company’s stock valued at $112,221,000 after acquiring an additional 3,328,506 shares during the period. Infinitum Asset Management LLC raised its stake in Biohaven by 267.6% during the 4th quarter. Infinitum Asset Management LLC now owns 6,250,000 shares of the company’s stock valued at $70,562,000 after acquiring an additional 4,550,000 shares during the last quarter. State Street Corp raised its stake in Biohaven by 34.2% during the 4th quarter. State Street Corp now owns 5,716,487 shares of the company’s stock valued at $64,539,000 after acquiring an additional 1,458,204 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Biohaven by 52.9% during the 4th quarter. Vanguard Group Inc. now owns 4,395,946 shares of the company’s stock valued at $49,630,000 after acquiring an additional 1,520,756 shares during the last quarter. 88.78% of the stock is owned by hedge funds and other institutional investors.

Biohaven Stock Performance

Shares of BHVN stock opened at $14.67 on Monday. The company has a current ratio of 7.41, a quick ratio of 7.41 and a debt-to-equity ratio of 1.87. The stock has a 50 day simple moving average of $13.95 and a 200-day simple moving average of $11.63. The company has a market cap of $2.21 billion, a price-to-earnings ratio of -2.59 and a beta of 1.26. Biohaven Ltd. has a 12-month low of $7.48 and a 12-month high of $18.57.

Analyst Ratings Changes

Several research analysts have weighed in on BHVN shares. Needham & Company LLC set a $11.00 target price on Biohaven in a research note on Monday, June 29th. Morgan Stanley cut their price target on Biohaven from $21.00 to $18.00 and set an “overweight” rating for the company in a research note on Wednesday, May 13th. Canaccord Genuity Group assumed coverage on Biohaven in a report on Monday, April 13th. They set a “buy” rating and a $21.00 price target for the company. Raymond James Financial reiterated a “strong-buy” rating on shares of Biohaven in a research report on Wednesday, May 27th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Biohaven in a research note on Tuesday, June 2nd. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Biohaven currently has an average rating of “Moderate Buy” and a consensus target price of $21.62.

About Biohaven

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.